Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid

Affiliations

¹ Department of Dermatology, University Hospital of Ioannina, Greece. Electronic address: ritsagravani@gmail.com.
² Department of Endocrinology and Diabetes Centre, University Hospital of Ioannina, Ioannina, Greece.
³ Department of Endocrinology and Diabetes Centre, University Hospital of Ioannina, Ioannina, Greece; Department of Endocrinology and Diabetes Centre, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
⁴ Department of Dermatology, University Hospital of Ioannina, Ioannina, Greece; Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

Agoritsa Gravani et al. An Bras Dermatol. 2021 Nov-Dec.

. 2021 Nov-Dec;96(6):782-784.

doi: 10.1016/j.abd.2020.10.010. Epub 2021 Sep 30.

¹ Department of Dermatology, University Hospital of Ioannina, Greece. Electronic address: ritsagravani@gmail.com.
² Department of Endocrinology and Diabetes Centre, University Hospital of Ioannina, Ioannina, Greece.
³ Department of Endocrinology and Diabetes Centre, University Hospital of Ioannina, Ioannina, Greece; Department of Endocrinology and Diabetes Centre, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
⁴ Department of Dermatology, University Hospital of Ioannina, Ioannina, Greece; Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

No abstract available

References

1. Gravani A., Gaitanis G., Tsironi T., Tigas S., Bassukas I.D. Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors. J Eur Acad Dermatol Venereol. 2018;32:e438–e439. - PubMed
1. Egesi A., Sun G., Khachemoune A., Rashid R.M. Statins in skin: research and rediscovery, from psoriasis to sclerosis. J Drugs Dermatol. 2010;9:921–927. - PubMed
1. Jha A., Ryu M.H., Oo O., Bews J., Carlson C., Scwartz J., et al. Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. Br J Pharmacol. 2018;175:1004–1016. - PMC - PubMed
1. Guo J.Y., Chen H.H., Yang Y.C., Wu P.Y., Chang M.P., Chen C.C. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study. J Diabetes Complications. 2020;34 - PubMed
1. Nishie W., Tasanen K. Gliptin-associated bullous pemphigoid: A valuable model of the mechanism of breakdown of immune tolerance against BP180. J Invest Dermatol. 2019;139:755–756. - PubMed